Holen Sie sich die Stockscreener-App
4.42
0.90%
-0.04
Handel nachbörslich:
4.52
0.10
+2.26%
Schlusskurs vom Vortag:
$4.46
Offen:
$4.45
24-Stunden-Volumen:
730.49K
Relative Volume:
0.83
Marktkapitalisierung:
$424.34M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-238.77M
KGV:
-0.1649
EPS:
-26.808
Netto-Cashflow:
$-216.62M
1W Leistung:
+1.14%
1M Leistung:
+25.57%
6M Leistung:
-13.33%
1J Leistung:
-64.75%
1-Tages-Spanne:
$4.21
$4.57
1-Wochen-Bereich:
$4.10
$4.655
52-Wochen-Spanne:
$2.7601
$13.11
Alumis Inc Stock (ALMS) Company Profile
Firmenname
Alumis Inc
Sektor
Branche
Telefon
650-231-6625
Adresse
280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO
Vergleichen Sie ALMS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ALMS
Alumis Inc
|
4.42 | 447.84M | 0 | -238.77M | -216.62M | -26.81 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 96.01B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 57.86B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 57.02B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.10B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.45B | 3.81B | -644.79M | -669.77M | -6.24 |
Alumis Inc Stock (ALMS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-25 | Eingeleitet | Wells Fargo | Overweight |
| 2025-06-10 | Fortgesetzt | Guggenheim | Buy |
| 2025-01-30 | Eingeleitet | Oppenheimer | Outperform |
| 2024-10-31 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-10-17 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-07-23 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-07-23 | Eingeleitet | Guggenheim | Buy |
| 2024-07-23 | Eingeleitet | Leerink Partners | Outperform |
| 2024-07-23 | Eingeleitet | Morgan Stanley | Overweight |
Alle ansehen
Alumis Inc Aktie (ALMS) Neueste Nachrichten
Alumis Misses Q2 Revenue as Costs Jump - The Motley Fool
Alumis Hits Major Milestone in Psoriasis Drug Development, Strengthens Pipeline with $486M War Chest - Stock Titan
While institutions invested in Alumis Inc. (NASDAQ:ALMS) benefited from last week's 4.1% gain, individual investors stood to gain the most - uk.finance.yahoo.com
Alumis Inc.'s (NASDAQ:ALMS) market cap touched US$444m last week, benefiting both retail investors who own 38% as well as institutions - simplywall.st
Alumis Inc. Concludes 2025 Annual Stockholders Meeting - The Globe and Mail
How strong is Alumis Inc. company’s balance sheetMassive stock growth - Jammu Links News
What is the dividend policy of Alumis Inc. stockGet alerts on high-potential stock breakouts - Jammu Links News
Should I hold or sell Alumis Inc. stock in 2025Build a portfolio that outperforms consistently - Jammu Links News
When is Alumis Inc. stock expected to show significant growthBuild a winning portfolio with smart picks - Jammu Links News
What drives Alumis Inc. stock priceInvest confidently with real-time data analysis - Jammu Links News
How volatile is Alumis Inc. stock compared to the marketInvest in stocks with strong fundamentals - Jammu Links News
What are analysts’ price targets for Alumis Inc. in the next 12 monthsCapitalize on trading strategies that deliver - Jammu Links News
What institutional investors are buying Alumis Inc. stockTurn volatility into profit opportunities - Jammu Links News
How many analysts rate Alumis Inc. as a “Buy”Build wealth steadily with expert advice - Jammu Links News
Confident Outlook on Acelyrin-Alumis Merger Amid Shareholder Opposition - TipRanks
How does Alumis Inc. compare to its industry peersDaily Trading Outlook With Proven Results - Jammu Links News
Is Alumis Inc. a growth stock or a value stockStock Strategy Tracker For Every Investor - Jammu Links News
What makes Alumis Inc. stock price move sharplyAI Driven Stock Trend Forecast Shows Momentum Shift - metal.it
Alumis (ALMS) Merges with ACELYRIN - Insider Monkey
What is the risk reward ratio of investing in Alumis Inc. stockHarness the power of proven investment plans - jammulinksnews.com
Alumis Inc.: Promising Pipeline and Strategic Advancements Justify Buy Rating - TipRanks
How does Alumis Inc. generate profit in a changing economyPre Market Target Finder For 2025 - Jammu Links News
What markets is Alumis Inc. expanding into Is ELPW stock a good long term investment optionMaximize returns with smart investment plans - Jammu Links News
Is Alumis Inc. stock a good hedge against inflationBest Stocks for Capital Safety - metal.it
What analysts say about Alumis Inc. stockAccelerated capital growth - PrintWeekIndia
Alumis Inc. Stock Analysis and ForecastFree Investment Community - PrintWeekIndia
Alumis Inc.: Buy Rating Affirmed Amid Promising ESK-001 Developments and Strong Financial Projections - TipRanks
Alumis initiated with an Overweight at Wells Fargo - TipRanks
What institutions are buying Alumis Inc. stock nowExplosive wealth accumulation - Jammu Links News
Is Alumis Inc. a good long term investmentSuperior capital gains - PrintWeekIndia
Finanzdaten der Alumis Inc-Aktie (ALMS)
Umsatz
Nettogewinn
Free Cashflow
ENV
Alumis Inc-Aktie (ALMS) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Tananbaum James B. | Director |
May 06 '25 |
Buy |
4.34 |
20,000 |
86,800 |
4,247,670 |
| Foresite Labs, LLC | 10% Owner |
May 02 '25 |
Buy |
4.62 |
25,000 |
115,500 |
4,227,670 |
| Foresite Labs, LLC | 10% Owner |
May 06 '25 |
Buy |
4.34 |
20,000 |
86,800 |
4,247,670 |
| Foresite Capital Management VI | 10% Owner |
May 02 '25 |
Buy |
4.62 |
25,000 |
115,500 |
4,227,670 |
| Foresite Capital Management VI | 10% Owner |
May 06 '25 |
Buy |
4.34 |
20,000 |
86,800 |
4,247,670 |
| AKKARAJU SRINIVAS | Director |
May 05 '25 |
Buy |
4.67 |
160,370 |
749,676 |
3,586,788 |
| AKKARAJU SRINIVAS | Director |
May 02 '25 |
Buy |
4.55 |
159,920 |
727,636 |
3,426,418 |
| Colowick Alan | Director |
Apr 01 '25 |
Buy |
6.97 |
16,104 |
112,309 |
16,104 |
| Colowick Alan | Director |
Apr 02 '25 |
Buy |
7.49 |
2,300 |
17,235 |
18,404 |
| Babler Martin | President, CEO and Chairman |
Apr 01 '25 |
Buy |
6.44 |
15,650 |
100,733 |
106,454 |
1.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):